These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7796965)

  • 1. Non-target effects of live vaccines: myth, reality and demagoguery.
    Levine MM
    Dev Biol Stand; 1995; 84():33-8. PubMed ID: 7796965
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety aspects in the development of an infectious bovine rhinotracheitis marker vaccine.
    Strube W; Abar B; Bergle RD; Block W; Heinen E; Kretzdorn D; Rodenbach C; Schmeer N
    Dev Biol Stand; 1995; 84():75-81. PubMed ID: 7796970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of current preclinical testing strategies for viral vaccines.
    Wood DJ
    Dev Biol Stand; 1998; 95():19-23. PubMed ID: 9855410
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of live pseudorabies virus vaccines.
    Kimman TG; Gielkens AL; Glazenburg K; Jacobs L; de Jong MC; Mulder WA; Peeters BP
    Dev Biol Stand; 1995; 84():89-96. PubMed ID: 7796972
    [No Abstract]   [Full Text] [Related]  

  • 5. Risks and benefits of vaccinia-vectored vaccine from the regulatory perspective.
    Marcus-Sekura CJ; Quinnan GV
    Res Virol; 1989; 140(5):467-9; discussion 487-91. PubMed ID: 2685956
    [No Abstract]   [Full Text] [Related]  

  • 6. New developments in the construction of safer and more versatile pseudorabies virus vaccines.
    Mettenleiter TC
    Dev Biol Stand; 1995; 84():83-7. PubMed ID: 7796971
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulatory issues relating to the use of recombinant vectors in production of human vaccines.
    Marcus-Sekura CJ
    Dev Biol Stand; 1994; 82():107-12. PubMed ID: 7958464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of vaccine vectors.
    Dorner F
    Dev Biol Stand; 1995; 84():23-32. PubMed ID: 7796959
    [No Abstract]   [Full Text] [Related]  

  • 9. Pediatric drug development in anesthesiology: an FDA perspective.
    Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
    Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
    [No Abstract]   [Full Text] [Related]  

  • 10. The influence of recombination on the genetic stability of pseudorabies vaccine virus.
    Visser N
    Dev Biol Stand; 1995; 84():97-104. PubMed ID: 7796973
    [No Abstract]   [Full Text] [Related]  

  • 11. A view on regulatory aspects of live viral vaccine safety.
    Horaud F
    Dev Biol Stand; 1994; 82():113-8. PubMed ID: 7958465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Is vaccination dangerous?].
    Nøkleby H
    Tidsskr Nor Laegeforen; 1997 Sep; 117(22):3186. PubMed ID: 9411852
    [No Abstract]   [Full Text] [Related]  

  • 13. Environmental hazard assessment of Venezuelan equine encephalitis virus vaccine candidate strain V3526.
    Rao V; Hinz ME; Roberts BA; Fine D
    Vaccine; 2004 Jun; 22(20):2667-73. PubMed ID: 15193393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine developments.
    Lancet; 1991 Apr; 337(8745):824-5. PubMed ID: 1672919
    [No Abstract]   [Full Text] [Related]  

  • 15. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vaccination of immunocompromised patients].
    Nøkleby H
    Tidsskr Nor Laegeforen; 2002 Nov; 122(28):2711-2. PubMed ID: 12523091
    [No Abstract]   [Full Text] [Related]  

  • 17. Human vaccines.
    Ada GL
    Dev Biol Stand; 1994; 82():181-8. PubMed ID: 7958473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Are vaccines for children safe enough?].
    Heilmann CJ
    Ugeskr Laeger; 2000 Aug; 162(34):4513. PubMed ID: 10981214
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccine INDs: review of clinical holds.
    Miller DL; Ross JJ
    Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.